Pharvaris (PHVS) Change in Accured Expenses (2020 - 2026)
Pharvaris (PHVS) posted Change in Accured Expenses of -$5.1 million for Q1 2026, down 483.42% on a QoQ basis from $1.3 million in Q4 2025, and down 812.72% year-over-year from $718004.1 in Q1 2025.
Pharvaris (PHVS) Change in Accured Expenses (2020 - 2026) Analysis & Trends
Pharvaris' Change in Accured Expenses history runs 7 years deep, the most recent figure standing at -$5.1 million for Q1 2026.
- Quarterly Change in Accured Expenses fell 812.72% year-over-year to -$5.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.7 million (down 10.39% YoY) and the FY2025 annual result came in at $7.0 million, up 47.7% from the prior year.
- Change in Accured Expenses was -$5.1 million for Q1 2026 at Pharvaris, down from $1.3 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $1033.0 billion in Q3 2023 and bottomed at -$1033.3 billion in Q2 2023.
- A 5-year average of -$17.9 million and a median of $1.2 million in 2022 frame the typical range for Change in Accured Expenses.
- Peak annual rise in Change in Accured Expenses reached 86970295.74% in 2023, while the deepest fall reached 36593338.77% in 2023.
- Pharvaris' Change in Accured Expenses stood at $894776.3 in 2022, then tumbled by 212.17% to -$1.0 million in 2023, then soared by 607.72% to $5.1 million in 2024, then plunged by 73.81% to $1.3 million in 2025, then plunged by 483.42% to -$5.1 million in 2026.
- Business Quant data shows PHVS's Change in Accured Expenses at -$5.1 million in Q1 2026, $1.3 million in Q4 2025, and $4.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 1.13 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -16.82 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 23.10 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 107.70 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -16.74 Mn |
| 10 | Pharvaris | 2.17 Bn | 1.88 Bn | - | -5.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.12 Mn |
| Mar 31, 2026 | -5.12 Mn |
| Dec 31, 2025 | 1.33 Mn |
| Dec 31, 2025 | 1.33 Mn |
| Sep 30, 2025 | 4.85 Mn |
| Sep 30, 2025 | 4.85 Mn |
| Jun 30, 2025 | 1.67 Mn |
| Jun 30, 2025 | 1.67 Mn |
| Mar 31, 2025 | -560,671.24 |
| Mar 31, 2025 | -560,671.24 |
| Dec 31, 2024 | 5.10 Mn |
| Dec 31, 2024 | 5.10 Mn |
| Sep 30, 2024 | -4.45 Mn |
| Sep 30, 2024 | -4.45 Mn |
| Jun 30, 2024 | 2.97 Mn |
| Jun 30, 2024 | 2.97 Mn |
| Mar 31, 2024 | 1.02 Mn |
| Mar 31, 2024 | 1.02 Mn |
| Dec 31, 2023 | -1.00 Mn |
| Dec 31, 2023 | -1.00 Mn |